2005
DOI: 10.1590/s1516-84842005000400003
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Lorand- Metze I Rev. bras. hematol. hemoter. 2005;27(4):233-235

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
2
0
2

Year Published

2008
2008
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 8 publications
0
2
0
2
Order By: Relevance
“…Juntamente com o quadro clínico e os dados do hemograma, a imuno-fenotipagem é a principal avaliação diagnóstica e permite o diagnóstico diferencial com as outras síndromes linfoproliferativas (8,10) . A LLC e o LL são praticamente a mesma doença (11) .…”
Section: Relatos De Casosunclassified
“…Juntamente com o quadro clínico e os dados do hemograma, a imuno-fenotipagem é a principal avaliação diagnóstica e permite o diagnóstico diferencial com as outras síndromes linfoproliferativas (8,10) . A LLC e o LL são praticamente a mesma doença (11) .…”
Section: Relatos De Casosunclassified
“…Some studies show that ROR1 is not only expressed in CLL but also in other mature B lymphoid neoplasms (MBLN), among them mantle cell lymphoma (MCL), diffuse large b cell lymphoma (DLBCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). Although the function of ROR1 in these diseases is not clearly characterized, it can be suggested that ROR1 is a suitable marker for the discrimination of populations of mature anomalous cells of the B lineage (Barna et al, 2011; Kipps, 2022; Lorand‐Metze, 2005; Uhrmacher et al, 2011; Zhao et al, 2021). Furthermore, its expression has also been found in B‐acute lymphoblastic leukemia (B‐ALL) cells and in a variety of solid tumors, such as ovarian cancer (Barna et al, 2011; Broome et al, 2011; Choi et al, 2018; Peng, 2021).…”
Section: Introductionmentioning
confidence: 99%
“…Studies indicate an expression of ROR1 in approximately 95% of cases of CLL, while normal mature B lymphocytes, including CD5+ B cells, do not express ROR1, which makes it an attractive marker for the development of targeted therapies against CLL (Broome et al, 2011; Cui et al, 2016; Kipps, 2022; Lorand‐Metze, 2005; Pekarsky & Croce, 2019). Due to the promising role of ROR1 as a therapeutic target, monoclonal antibodies, bispecific antibodies, antibody‐drug conjugates, and anti‐ROR1 CAR‐T therapy are under development.…”
Section: Introductionmentioning
confidence: 99%
“…6 Na era do tratamento alvo-específico, já consagrado para algumas entidades, a demonstração da translocação/rearranjo gênico é fundamental para a indicação adequada do tratamento. 4 O diagnóstico de leucemia aguda é baseado na porcentagem de blastos na medula óssea, e os diversos subtipos são definidos por características fenotípicas e genotípicas (linhagem, maturação, etc O diagnóstico de síndrome mielodisplásica é baseado nos achados de hemograma, citologia de medula óssea e cariótipo. A biópsia de medula é importante para da medula óssea é fundamental (Tabela 1).…”
Section: Introductionunclassified